Financial Data and Key Metrics Changes - Total company revenues increased by 9.1% to $311 million for Q3 2025, with an adjusted EBITDA growth of 12.2% to $164 million, resulting in adjusted EBITDA margins of 52.7%, an increase of 147 basis points year-over-year [5][9][10] - Net income for Q3 2025 was $48 million, or $0.17 per diluted share, compared to $17 million, or $0.06 per diluted share in Q3 2024 [9][10] - Adjusted EPS increased by $0.09 to $0.26 compared to Q3 2024, driven by adjusted EBITDA growth and a reduced tax rate [10][17] Business Line Data and Key Metrics Changes - Sterigenics achieved 9.8% revenue growth to $193 million, with segment income increasing by 11.6% to $107 million and margins improving to 55.6% [10][11] - Nordion's revenue grew by 22.4% to $63 million, with segment income rising by 19.9% to approximately $38 million, although segment income margin decreased to 60.6% due to product mix [11][12] - Nelson Labs reported a 5% decline in revenue to $56 million, but segment income rose by 1.9% to $19 million, with margins expanding to 34.1% [12][13] Market Data and Key Metrics Changes - The company reaffirmed its 2025 revenue outlook and raised its adjusted EBITDA outlook, expecting constant currency revenue growth of 4.5%-6% and adjusted EBITDA growth of 6.75%-7.75% [15][16] - Nordion secured a 25-year renewal of its Class 1B operating license, enhancing its position in the global supply of Cobalt-60 [8] Company Strategy and Development Direction - The company emphasized its vital role in global healthcare and its commitment to operational excellence and safety culture [8][18] - Strategic actions taken included paying down $75 million of debt and lowering interest expenses, which are expected to generate approximately $13 million in annual savings [7][14] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued recovery of volumes across Sterigenics and other business lines, with expectations for sustained growth [25][31] - The company noted minimal impact from the government shutdown on its operations, with some indirect effects on expert advisory services [33][34] Other Important Information - The company is on track to achieve its cumulative free cash flow commitment of $500 million-$600 million from 2025 through 2027 [17] - The litigation update highlighted favorable rulings in ongoing cases, reinforcing the company's position regarding ethylene oxide emissions [18][22] Q&A Session Summary Question: Volume recovery in specific areas - Management noted consistent performance across Sterigenics and various categories, including bioprocessing and med tech, with expectations for continued volume recovery [25] Question: Broader litigation update - Management provided updates on ongoing cases in Illinois and Georgia, indicating progress and favorable rulings [27][28] Question: Expectations of budget flush in Q4 - Management does not expect a budget flush from med tech customers and feels confident in their guidance for the remainder of the year [31][33] Question: Expert advisory services impact - Management acknowledged that expert advisory services are feeling headwinds from FDA activity, impacting top-line performance [37] Question: Core lab testing growth - Management indicated that core lab testing is performing well, with some growth expected despite challenges in expert advisory services [42] Question: Nordion revenue growth and margin pressure - Management explained that margin pressure in Nordion is due to a mix of lower-margin product sales, but overall margins remain strong [48] Question: Sustainability of Sterigenics growth - Management reiterated confidence in Sterigenics' long-term growth trajectory, expecting mid to high single-digit growth [50] Question: Pricing trends in Sterigenics - Management noted that pricing contributions are stabilizing, with expectations for gradual improvements as capital investments are realized [52][56]

Financial Data and Key Metrics Changes - The company reported a total service revenue of $40.9 million for Q1 2025, an 11% increase compared to Q1 2024 [6][7] - Adjusted EBITDA for Q1 2025 was $5.3 million, reflecting a 14% increase year-over-year [6][7] - The company ended the quarter with $30.8 million in unrestricted cash [6] Business Segment Data and Key Metrics Changes - The servicer and real estate segment generated service revenue of $32.9 million, a 13% increase from Q1 2024, with adjusted EBITDA of $12 million, up 15% [11] - The origination segment reported service revenue of $8 million, a 3% increase year-over-year, with adjusted EBITDA remaining flat at $500,000 [13] - The corporate segment's adjusted EBITDA loss increased by $900,000 to $7.2 million, primarily due to nonrecurring benefits in the previous year [15] Market Data and Key Metrics Changes - The mortgage delinquency rate was reported at 1.3% in March 2025, slightly higher than the historical low of 1.1% in May 2024 [15] - Foreclosure starts increased by 25% in Q1 2025 compared to the same period in 2024, although they were 18% lower than in 2019 [15][16] - The origination market faced challenges, with a 1% decrease in industry-wide origination volume compared to Q1 2024 [20] Company Strategy and Development Direction - The company aims to diversify its revenue base and ramp up business won while maintaining cost discipline [21] - Focus is on accelerating growth in certain businesses that are expected to benefit from favorable market conditions [21] - The company is positioned to benefit from potential increases in mortgage delinquencies and foreclosure activity [21] Management's Comments on Operating Environment and Future Outlook - Management noted that while the economy and consumers face pressure, this could lead to higher mortgage delinquencies and foreclosure starts, which the company is well-positioned to capitalize on [21] - The company expressed confidence in its first-quarter results and its ability to navigate the current economic landscape [21] Other Important Information - The company successfully closed a transaction that reduced long-term debt by over $60 million, significantly strengthening its balance sheet [10] - The annual cash interest cost on the new debt is estimated to be approximately $9.5 million, down from $13 million previously [10] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded with management expressing satisfaction with the first-quarter performance [22][23]